tiprankstipranks
Advertisement
Advertisement

MBX Stock Latest News

MBX Biosciences price target raised to $88 from $70 at Truist
The FlyMBX Biosciences price target raised to $88 from $70 at Truist
4d ago
MBX
MBX Biosciences price target raised to $88 from $70 at Barclays
PremiumThe Fly
MBX Biosciences price target raised to $88 from $70 at Barclays
7d ago
MBX
MBX Biosciences reports Q2 EPS (78c), consensus (59c)
PremiumThe Fly
MBX Biosciences reports Q2 EPS (78c), consensus (59c)
8d ago
MBX
MBX Biosciences Advances Canvuparatide and Obesity Pipeline
PremiumCompany Announcements
MBX Biosciences Advances Canvuparatide and Obesity Pipeline
8d ago
8K
MBX
MBX Biosciences price target raised to $91 from $57 at Mizuho
PremiumThe Fly
MBX Biosciences price target raised to $91 from $57 at Mizuho
16d ago
MBX
MBX Biosciences price target raised to $90 from $60 at UBS
PremiumThe FlyMBX Biosciences price target raised to $90 from $60 at UBS
22d ago
MBX
MBX: Leadership Transition, Pipeline Visibility Support Maintained Buy Rating and Unchanged $91 Price Target
Premium
Ratings
MBX: Leadership Transition, Pipeline Visibility Support Maintained Buy Rating and Unchanged $91 Price Target
29d ago
MBX
Closing Bell Movers: Trex up 6% after positive Q2 pre-announcement
Premium
The Fly
Closing Bell Movers: Trex up 6% after positive Q2 pre-announcement
1M ago
FBK
LEU
MBX Biosciences Announces CEO Transition and Leadership Updates
PremiumCompany Announcements
MBX Biosciences Announces CEO Transition and Leadership Updates
1M ago
8K
MBX
MBX Biosciences CEO Kent Hawryluk steps down, Steve Hoerter succeeds
PremiumThe Fly
MBX Biosciences CEO Kent Hawryluk steps down, Steve Hoerter succeeds
1M ago
MBX
MBX Biosciences Completes STEADI Trial, Putting Imapextide on Investors’ Radar
PremiumCompany Announcements
MBX Biosciences Completes STEADI Trial, Putting Imapextide on Investors’ Radar
1M ago
MBX
Analyst Reiterates Buy on MBX, Maintains $91 Price Target on Canvuparade’s Once-Weekly Hypoparathyroidism Opportunity
PremiumRatings
Analyst Reiterates Buy on MBX, Maintains $91 Price Target on Canvuparade’s Once-Weekly Hypoparathyroidism Opportunity
2M ago
MBX
MBX Biosciences down 19% at $30.05 after announcing canvuparatide study results
PremiumThe FlyMBX Biosciences down 19% at $30.05 after announcing canvuparatide study results
2M ago
MBX
MBX Biosciences unveils positive Phase 2 canvuparatide results
Premium
Company Announcements
MBX Biosciences unveils positive Phase 2 canvuparatide results
2M ago
8K
MBX
MBX Biosciences announces results from Avail, canvuparatide trials
Premium
The Fly
MBX Biosciences announces results from Avail, canvuparatide trials
2M ago
MBX
MBX Biosciences Shareholders Approve Directors and Auditor
PremiumCompany Announcements
MBX Biosciences Shareholders Approve Directors and Auditor
2M ago
8K
MBX
MBX Biosciences price target raised to $56 from $50 at Stifel
PremiumThe Fly
MBX Biosciences price target raised to $56 from $50 at Stifel
3M ago
MBX
MBX Biosciences price target raised to $70 from $66 at Barclays
PremiumThe Fly
MBX Biosciences price target raised to $70 from $66 at Barclays
3M ago
MBX
MBX Biosciences price target raised to $86 from $76 at Citizens
PremiumThe Fly
MBX Biosciences price target raised to $86 from $76 at Citizens
3M ago
MBX
MBX Biosciences price target raised to $70 from $50 at Truist
PremiumThe FlyMBX Biosciences price target raised to $70 from $50 at Truist
3M ago
MBX
MBX Biosciences Phase 1 data supports once-monthly dosing for MBX 4291
Premium
The Fly
MBX Biosciences Phase 1 data supports once-monthly dosing for MBX 4291
3M ago
MBX
MBX Biosciences Highlights Positive Phase 1 Obesity Data
Premium
Company Announcements
MBX Biosciences Highlights Positive Phase 1 Obesity Data
3M ago
8K
MBX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >